Alpha 2.0
Login Register
» Articles » PMID: 24733411

Vedolizumab, a Gut-specific Monoclonal Antibody, Renews Hope for an Alternative to Anti-TNF Therapy in Inflammatory Bowel Diseases

Overview
Journal Ann Gastroenterol
Specialty Gastroenterology
Date 2014 Apr 16
PMID 24733411
Citations 2
Authors
Ali Rezaie
Affiliations
Soon will be listed here.
Citing Articles

Safety and effectiveness of vedolizumab in paediatric patients with inflammatory bowel disease: an observational multicentre Spanish study.

Garcia-Romero R, Martinez de Zabarte Fernandez J, Pujol-Muncunill G, Donat-Aliaga E, Segarra-Canton O, Irastorza-Terradillos I Eur J Pediatr. 2021; 180(9):3029-3038.

PMID: 33880650 DOI: 10.1007/s00431-021-04063-6.

Positioning Therapy for Ulcerative Colitis.

Grinspan A, Kornbluth A Curr Gastroenterol Rep. 2015; 17(8):29.

PMID: 26143627 DOI: 10.1007/s11894-015-0454-0.

References
1.
Feagan B, Rutgeerts P, Sands B, Hanauer S, Colombel J, Sandborn W . Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013; 369(8):699-710. DOI: 10.1056/NEJMoa1215734. View
2.
Sandborn W, Feagan B, Rutgeerts P, Hanauer S, Colombel J, Sands B . Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2013; 369(8):711-21. DOI: 10.1056/NEJMoa1215739. View
3.
Frolkis A, Dykeman J, Negron M, DeBruyn J, Jette N, Fiest K . Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies. Gastroenterology. 2013; 145(5):996-1006. DOI: 10.1053/j.gastro.2013.07.041. View
4.
Sandborn W . The future of inflammatory bowel disease therapy: where do we go from here?. Dig Dis. 2013; 30 Suppl 3:140-4. DOI: 10.1159/000342742. View
5.
Jovani M, Danese S . Vedolizumab for the treatment of IBD: a selective therapeutic approach targeting pathogenic a4b7 cells. Curr Drug Targets. 2013; 14(12):1433-43. DOI: 10.2174/13894501113146660206. View